AR009582A1 - Procedimiento de preparacion de un medicamento que contiene proteina plasmatica a partir de plasma citratado o a partir de una fraccion de plasmaque contiene citrato - Google Patents

Procedimiento de preparacion de un medicamento que contiene proteina plasmatica a partir de plasma citratado o a partir de una fraccion de plasmaque contiene citrato

Info

Publication number
AR009582A1
AR009582A1 ARP970104234A ARP970104234A AR009582A1 AR 009582 A1 AR009582 A1 AR 009582A1 AR P970104234 A ARP970104234 A AR P970104234A AR P970104234 A ARP970104234 A AR P970104234A AR 009582 A1 AR009582 A1 AR 009582A1
Authority
AR
Argentina
Prior art keywords
plasma protein
fraction
citrate
plasma
plasmaque
Prior art date
Application number
ARP970104234A
Other languages
English (en)
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3517640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR009582(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of AR009582A1 publication Critical patent/AR009582A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un método de preparacion de un medicamento que contiene proteína plasmática a partir de plasma citratado o a partir de una fraccionque contiene citrato, hallándose el medicamento sustancialmente exento de metalesindeseables , y comprendiendo el método las siguientes etapas:intercambiar el citrato y opcionalmente metales ligados al citrato, en una solucion que contiene proteína plasmática por un mono o dicarboxilato o ácidoorgánico mono o dicarboxílicosoluble en ag ua, bajo condiciones no precipitantes, recuperar la o las proteínas plasmáticas y terminar elmedicamento.
ARP970104234A 1996-09-16 1997-09-16 Procedimiento de preparacion de un medicamento que contiene proteina plasmatica a partir de plasma citratado o a partir de una fraccion de plasmaque contiene citrato AR009582A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0163396A AT403989B (de) 1996-09-16 1996-09-16 Verfahren zur herstellung eines plasmaprotein-hältigen arzneimittels

Publications (1)

Publication Number Publication Date
AR009582A1 true AR009582A1 (es) 2000-04-26

Family

ID=3517640

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104234A AR009582A1 (es) 1996-09-16 1997-09-16 Procedimiento de preparacion de un medicamento que contiene proteina plasmatica a partir de plasma citratado o a partir de una fraccion de plasmaque contiene citrato

Country Status (24)

Country Link
US (3) US20020034809A1 (es)
EP (1) EP0927195B1 (es)
JP (1) JP2001500867A (es)
KR (1) KR20000036002A (es)
CN (1) CN1230967A (es)
AR (1) AR009582A1 (es)
AT (2) AT403989B (es)
AU (1) AU732519B2 (es)
BR (1) BR9712044A (es)
CA (1) CA2265936C (es)
CZ (1) CZ91199A3 (es)
DE (1) DE59710700D1 (es)
DK (1) DK0927195T3 (es)
ES (1) ES2206701T3 (es)
HU (1) HUP0002265A3 (es)
ID (1) ID21224A (es)
IL (1) IL128770A0 (es)
IN (1) IN187314B (es)
MX (1) MXPA99002144A (es)
NO (1) NO991198L (es)
PL (1) PL332159A1 (es)
PT (1) PT927195E (es)
SK (1) SK32899A3 (es)
WO (1) WO1998012225A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2103236B1 (es) * 1996-01-30 1998-04-16 Grifols Grupo Sa Albumina humana terapeutica con baja capacidad para la fijacion de aluminio.
AT407484B (de) * 1997-11-12 2001-03-26 Bio Prod & Bio Eng Ag Arzneimittel zur förderung der wundheilung
AT408946B (de) * 1999-02-18 2002-04-25 Immuno Ag Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation
JP2003040798A (ja) * 2001-07-26 2003-02-13 Nihon Pharmaceutical Co Ltd 低アルミニウム含有アルブミン製剤およびその製造法
IL162239A0 (en) 2001-12-21 2005-11-20 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
AT501088A2 (de) * 2002-12-18 2006-06-15 Bio Prod & Bio Eng Ag Stabile therapeutische proteine
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
JP5627832B2 (ja) * 2003-05-23 2014-11-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 溶液中におけるタンパク質の安定化
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第vii因子ポリペプチドの液状水性医薬組成物
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
MX354995B (es) 2011-12-05 2018-03-27 Factor Bioscience Inc Metodos y productos para transfeccion de celulas.
ES2381828B1 (es) * 2012-03-20 2012-11-16 Grifols, S.A. PROCEDIMIENTO PARA OBTENER UNA COMPOSICION DE IgG MEDIANTE TRATAMIENTO TERMICO
CA3067735A1 (en) 2017-08-17 2019-02-21 Just Biotherapeutics, Inc. Method of purifying glycosylated protein from host cell galectins and other contaminants

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384134C (de) * 1921-05-07 1923-10-25 Chemisch Pharmazeutische Werke Verfahren zur Herstellung eines Kamillenextraktes
DE2331854A1 (de) * 1973-06-22 1975-01-16 Greither Salus Haus Dr Otto Verfahren zur herstellung standardisierter arzneimittel aus kamillenblueten
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
SE500110C2 (sv) * 1989-06-27 1994-04-18 Kabi Pharmacia Ab Sätt att rena ett protein från därtill bundna flervärda metalljoner
US5250663A (en) * 1990-04-19 1993-10-05 Miles Inc. Preparing essentially monomeric normal human serum albumin
JP2949846B2 (ja) * 1990-11-30 1999-09-20 吉富製薬株式会社 アルブミン製剤の保存方法
US5561115A (en) * 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
ES2103236B1 (es) * 1996-01-30 1998-04-16 Grifols Grupo Sa Albumina humana terapeutica con baja capacidad para la fijacion de aluminio.
US5744586A (en) * 1996-06-26 1998-04-28 Alpha Therapeutic Corporation Manufacturing process for the production of purified transferrin
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies

Also Published As

Publication number Publication date
CZ91199A3 (cs) 1999-06-16
AU732519B2 (en) 2001-04-26
ES2206701T3 (es) 2004-05-16
EP0927195A2 (de) 1999-07-07
CA2265936C (en) 2008-04-22
AT403989B (de) 1998-07-27
US20020034809A1 (en) 2002-03-21
NO991198D0 (no) 1999-03-11
ID21224A (id) 1999-05-06
IN187314B (es) 2002-03-23
ATA163396A (de) 1997-12-15
JP2001500867A (ja) 2001-01-23
US8709492B2 (en) 2014-04-29
US20140234292A1 (en) 2014-08-21
ATE248857T1 (de) 2003-09-15
CN1230967A (zh) 1999-10-06
AU4289997A (en) 1998-04-14
HUP0002265A3 (en) 2003-01-28
DK0927195T3 (da) 2003-11-24
WO1998012225A2 (de) 1998-03-26
DE59710700D1 (de) 2003-10-09
PL332159A1 (en) 1999-08-30
BR9712044A (pt) 1999-08-24
PT927195E (pt) 2004-01-30
CA2265936A1 (en) 1998-03-26
KR20000036002A (ko) 2000-06-26
HUP0002265A2 (hu) 2000-11-28
NO991198L (no) 1999-05-14
WO1998012225A3 (de) 1998-04-23
MXPA99002144A (es) 2005-04-28
SK32899A3 (en) 1999-08-06
US20050249815A1 (en) 2005-11-10
EP0927195B1 (de) 2003-09-03
IL128770A0 (en) 2000-01-31

Similar Documents

Publication Publication Date Title
AR009582A1 (es) Procedimiento de preparacion de un medicamento que contiene proteina plasmatica a partir de plasma citratado o a partir de una fraccion de plasmaque contiene citrato
DE59407237D1 (de) Nitrato-aminosäure-disulfide zur therapie von erkrankungen des herz-kreislauf-systems
DE69033600T2 (de) Verfahren zur Isolierung von Haemopnilus influenzae Protein-E
HUP0204281A2 (hu) Eljárás glukagonszerű peptid-1 vegyületek szolubiliázálására
ATE184480T1 (de) Verfahren zur herstellung von arzneizubereitungen mit verzögerter wirkstoffabgabe
DE59002438D1 (de) L-Carnitin-Magnesium-Zitrat.
FR2439789A1 (fr) Procede pour la preparation de n-phosphonomethylglycine
DE69809962D1 (de) Verfahren zur herstellung von hydroxysubstituierten gamma-butyrolactonen
ATE203907T1 (de) Dermatologische zubereitung zur behandlung von aktinischen keratosen
ATE439833T1 (de) Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
FR2771292B1 (fr) Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
PL328712A1 (en) Anionic salts of non-narcotic analgetic agents of carboxylic acid type combined with morphine and diamorphine, method of obtaining them, their application and pharmaceutic agents containing such salts
IE40555B1 (en) Pharmaceutically active proteinaceous compounds
DK0557389T3 (da) Fremgangsmåde til fremstilling af tabletter indeholdende cephalosporansyrederivater ved direkte komprimering
ATE111455T1 (de) 3-substituierte 1,2,3,4-oxatriazol-5- iminderivate, verfahren zur herstellung sowie diese enthaltende arzneimittel.
DE69522702T2 (de) Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält
DE69707901T2 (de) Verfahren zur herstellung von kontrastmitteln
AU8169491A (en) Process for the recovery of rhodium from the residues of the distillation of products of the oxo process
NZ516235A (en) Method for purification of proteins
ATE232867T1 (de) Tetronsäurederivate zur behandlung von hiv- und anderen retroviruserkrankungen
FI961505A0 (fi) Uudet veren koaguloitumisjärjestelmässä terapeuttisesti aktiiviset peptidiyhdisteet, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
ZA824649B (en) New optically active dipeptides, process for their preparation and pharmaceutical products containing these compounds
SE9804248D0 (sv) Anti-coagulation with calcium containing citrate solution
ATE345124T1 (de) Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia
RU2003120501A (ru) Способ лечения миокардиострофии